Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
复制标题
DOI：
10.1126/science.abb5920
复制
发表时间：
2021-02-05
期刊：
影响因子：
56.9
通讯作者：
Boursi, Ben
中科院分区：
文献类型：
--
作者：
Baruch, Erez N.;Youngster, Ilan;Boursi, Ben
在临床前小鼠模型和观察性患者队列中，肠道微生物组已被证明会影响肿瘤对抗PD-1（程序性细胞死亡-1）免疫治疗的反应。然而，尚未在临床试验中研究癌症患者肠道微生物群的调节。在这项研究中，我们进行了一项I期临床试验，以评估粪便微生物群移植（FMT）和抗PD-1免疫治疗在10例抗PD-1难治性转移性黑色素瘤患者中的安全性和可行性。我们观察了3例患者的临床反应，包括2例部分反应和1例完全反应。值得注意的是，FMT治疗与肠道固有层和肿瘤微环境中免疫细胞浸润和基因表达谱的有利变化相关。这些早期发现对调节癌症治疗中的肠道微生物群具有重要意义。
The gut microbiome has been shown to influence the response of tumors to anti-PD-1 (programmed cell death-1) immunotherapy in preclinical mouse models and observational patient cohorts. However, modulation of gut microbiota in cancer patients has not been investigated in clinical trials. In this study, we performed a phase 1 clinical trial to assess the safety and feasibility of fecal microbiota transplantation (FMT) and reinduction of anti-PD-1 immunotherapy in 10 patients with anti-PD-1-refractory metastatic melanoma. We observed clinical responses in three patients, including two partial responses and one complete response. Notably, treatment with FMT was associated with favorable changes in immune cell infiltrates and gene expression profiles in both the gut lamina propria and the tumor microenvironment. These early findings have implications for modulating the gut microbiota in cancer treatment.